Relugolix for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Mar 2023: Trial registered, NCT05765500
  2. 12 Feb 2024: Trial started, NCT05765500

The trials

NCT05765500: RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

State
Under way
Phase
Phase 2
People
110 planned
Started
12 Feb 2024
Primary completion
1 Jul 2027
Arms
Arm A: Relugolix
Results
None posted
  1. 13 Mar 2023: Trial registered
  2. 12 Feb 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Myfembree component relugolix, Orgovyx.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.